The EU Court of Justice clarifies when patent settlement agreements restricting a generic pharmaceutical company’s ability to enter the market, infringe EU antitrust rules (Generics - UK)

Article summary: Settlement Agreements Can Be Anti-Competitive Only If The Involved Companies Are (At Least) Potential Competitors. A Careful Examination Must Determine Whether A Generic Manufacturer Would Have Entered Into The Market Without A "Pay Per Delay" Agreement. The Classification Of This Kind Of Patent Agreement As A Restriction Of Competition "By Object" Is Not Self-Evident. Whether There Is A Restriction "By Effect" It Must Be Determined Based On A Prospective Analysis Of The Market In The Absence Of The Concerted Practice. The Assessment Of A Dominant Position Of A Patent Holder Requires Balancing The Anti-Competitive Effects Of The Allegedly Abusive Conduct And Its Efficiencies. Introduction On 30 January 2020, the Court of Justice of the European Union (the ‘CJEU’)

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

Citation

Anne Federle, Pauline Van Sande, The EU Court of Justice clarifies when patent settlement agreements restricting a generic pharmaceutical company’s ability to enter the market, infringe EU antitrust rules (Generics - UK), 30 janvier 2020, e-Competitions January 2020, Art. N° 95846

Visites 60

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues